

Ahmed S. Attia Ph.D.

I- Basic Information:

Name	Ahmed Sherif Mohamed Hussein Attia		
Gender	Male		
Address	Faculty of Pharmacy, Cairo University, Kasr El-Ainy St, Cairo, Egypt, 11562		
Tel Number	+020-2-24157145	Mobile	+020-0106-5344060
Email	ahmed.attia@pharma.cu.edu.eg		
Website	https://sites.google.com/site/ahmedsattia		
Date of birth	Day:13	Mo:12	Yr:1974

II- Education:

Degree obtained	Dates
Ph.D. (Molecular Microbiology) from University of Texas Southwestern Medical Centre at Dallas, USA.	2001-2006
M.Sc. (Microbiology & Immunology) from Faculty of Pharmacy, Cairo University, Cairo, Egypt.	1998-2001
BSc (Pharmaceutical Sciences) from Faculty of Pharmacy, Cairo University, Cairo, Egypt.	1992-1997

III- Academic Positions:

Employer	Position	Dates (from – to)
Faculty of Pharmacy, Cairo University, Cairo, Egypt	Professor	7/2017 - current
School of Pharmacy, Newgiza University, Giza, Egypt	Adjunct Faculty	10/2016 - current
Faculty of Pharmacy, Cairo University, Cairo, Egypt	Assistant Professor	6/2012 - 7/2017
Faculty of Dentistry, British University of Egypt, Cairo, Egypt	Adjunct Faculty	10/2011 - 5/2017
Faculty of Pharmacy, Cairo University, Cairo, Egypt	Lecturer	6/2007 - 5/2012
Vanderbilt University Medical Centre, Nashville, TN, USA	Postdoctoral research fellow	9/2008 - 9/2010
University of Texas Southwestern Medical Center, Dallas, TX, USA	Postdoctoral research fellow	4/2006 - 6/2007
University of Texas Southwestern Medical Centre, Dallas, TX, USA	Graduate research assistant	8/2001 - 3/2006
Faculty of Pharmacy, Cairo University, Cairo, Egypt	Teaching assistant	12/1997 - 8/2001

IV- Administrative positions:

Employer	Position	Dates (from – to)
Supreme Council of Universities	Member of the Permanent Committee for the Promotion of Professors and Assistant Professors (Pharmaceutical Microbiology & Immunology)	09-2022- current
Faculty of Pharmacy, Cairo University, Cairo, Egypt	Coordinator of the Clinical Pharmacy Program	12/2017- 02/2020
Faculty of Pharmacy, Cairo University, Cairo, Egypt	Vice Coordinator of the Clinical Pharmacy Program	10/2010 -11/2017

V- Membership of professional associations:

National Committee for Microbiological Sciences
American Society for Microbiology
British Society for Antimicrobial Chemotherapy
Egyptian Pharmacist Syndicate
World Association of Young Scientists

VI- Fields of interest:

Molecular Pathogenesis, Immunology, Medical Biotechnology, Therapeutics Development, Immunoinformatics, Microbial Diagnostics

VII- Awards / distinctions:

	Award	Country	Year
1.	Advancing Healthcare Innovation in Africa (AHIA) as an innovator	USA	2019
2.	Cairo University International Publication Award	Egypt	2019
3.	Cairo University International Publication Award	Egypt	2018
4.	Dr. Ikram Abdel Salam Award in Medical Genetics	Egypt	2017
5.	Cairo University International Publication Award	Egypt	2017
6.	Cairo University Scientific Excellence Award in Advanced Technological Sciences	Egypt	2016
7.	Cairo University International Publication Award	Egypt	2016
8.	Cairo University International Publication Award	Egypt	2015
9.	Misr El-Kheir (MEK) Publication Award	Egypt	2014

10.	Cairo University International Publication Award	Egypt	2014
11.	The Saving Lives at Birth Incubator Award	International	2013
12.	Cairo University Encouraging Award in Advanced Technological Sciences	Egypt	2013
13.	The State Encouraging Award in Advanced Technological Sciences Serving Medical Sciences.	Egypt	2013
14.	Cairo University International Publication Award	Egypt	2013
15.	Faculty of Pharmacy, Cairo University, Best International Publication in Microbiology in 2012	Egypt	2013
16.	Faculty of Pharmacy, Cairo University 3 rd distinction week Award	Egypt	2012
17.	Misr El-Kheir (MEK) Publication Award	Egypt	2011
18.	Cairo University International Publication Award	Egypt	2011
19.	Faculty of Pharmacy, Cairo University 2 nd distinction week Award	Egypt	2011
20.	Cairo University International Publication Award	Egypt	2010
21.	Sidney P. Colowick Award for Outstanding Postdoctoral Fellow Vanderbilt University Nashville, TN, USA	USA	2010
22.	Cairo University International Publication Award	Egypt	2009

VIII- Training:

	Training attended	Date
1.	Introduction to Infection Prevention and Control (IPC) offered through OpenWHO	Jan 2022
2.	Influenza Prevention and Control offered through OpenWHO	Jan 2022
3.	Antimicrobial Stewardship: A Competency-based Approach offered through OpenWHO	Dec 2021
4.	Total Quality Management in HealthCare organized by FLDC-CU.	May 2017
5.	Ethical Considerations for Animal Use in Research & Education organized by FLDC-CU.	May 2017
6.	International Publication organized by FLDC-CU.	Oct 2015
7.	University Management organized by FLDC-CU.	May 2015
8.	Organization of Scientific Conferences organized by FLDC-CU.	Feb 2015
9.	Creative Thinking organized by FLDC-CU.	Dec 2014
10.	Time Management organized by FLDC-CU.	Jun 2014

11.	Leadership of Scientific Team organized by FLDC-CU.	Feb 2014
12.	Incubator Awardee Training Program Saving Lives at Birth Grand Challenge Nairobi, Kenya organized by USAID, the Government of Norway, the Bill & Melinda Gates Foundation, Grand Challenges Canada, and DFID	Dec 2013
13.	E-learning organized by FLDC-CU.	Sept 2013
14.	Effective Teaching Skills organized by FLDC-CU.	Mar 2013
15.	Examination Techniques & Student Evaluation organized by FLDC-CU.	Jan 2012
16.	Legal & Financial Affairs in the University organized by FLDC-CU.	July 2011
17.	Research Team Management organized by FLDC-CU.	April 2011
18.	Research Ethics organized by FLDC-CU.	Jan 2011
19.	How to Compete for a Research Fund organized by FLDC-CU.	Feb 2011
20.	Academic Advising organized by CIQAP, Faculty of Pharmacy, Cairo University.	Oct 2010
21.	The Credit Hours System organized by FLDC-CU.	Aug 2008

IX-Teaching activities:

1- Taught the following courses to students (undergraduate and postgraduate) in Cairo University, local governmental universities. and private universities in **lecture hall-based format:**

Course	Stage/Program/University
Cell Biology	Undergraduate/Clinical Program/Cairo University
Public Health	Undergraduate/Regular Program/ Cairo University Undergraduate/Clinical Program/ Cairo University Undergraduate/ Misr International University (MIU)
Medical Microbiology	Undergraduate/Clinical Program/Cairo University Undergraduate/Clinical Program/ Beni Suef University Undergraduate/Ahram Canadian University (ACU) Undergraduate/ Misr International University (MIU)
Immunology	Undergraduate/Clinical Program/Cairo University Undergraduate/Clinical Program/ Beni Suef University
Medical Microbiology for Dental Students	Undergraduate/ 6 th October Modern Sciences and Arts (MSA) University Undergraduate/ British University in Egypt (BUE)
Medical Microbiology for Nursing Students	Undergraduate/Cairo University
General Microbiology	Undergraduate/Ahram Canadian University (ACU)

Parasitology	Undergraduate/Regular Program/ Cairo University
Immunology	Postgraduate/Pre-Master/Cairo University
Advanced Microbiology	Postgraduate/Pre-Master/Cairo University
Molecular Biology	Postgraduate/Biotechnology Diploma/Cairo University
Immune disorders and infectious diseases	Postgraduate/PharmD/Cairo University
Pharmaceutical Bioinformatics	Postgraduate/Drug Discovery Diploma/Cairo University
Antimicrobial and Immunological Drug Discovery	Postgraduate/Genomics & Bioinformatics Diploma/Cairo University

2- Taught the following courses in **E-learning (distance education)** based format:

Course	Stage/Program/ University	E-learning portal	Enrolled Students
Cell Biology	Undergraduate/Clinical Program/Cairo University	- National E-learning Center (NELC) 2011/2012 to 2014/2015 - Course Builder/google-appspot (2015/2016) to (2018/2019) - Blackboard Platform (2020-2021)	250 to 380/class
Parasitology	Undergraduate/Regular Program/ Cairo University	Google Classroom (2015/2016) to (2018/2019)	850-950/class
Immunology	Undergraduate/Clinical Program/Cairo University	Course Builder/google-appspot (2015/2016) to (2019/2020) - Blackboard Platform (2020-2021)	250 to 380/class
Clinical Microbiology	Undergraduate/Clinical Program/Cairo University	Google Classroom (2016/2017) to (2019/2020) - Blackboard Platform (2020-2021)	250 to 380/class

X- Graduate students mentoring activities:

Mentor on the following thesis projects:

A) Finished thesis project:

i- Ph.D. thesis projects:

1. "Study on isocitratelase (s) of the glycoxylate shunt of *Mycobacterium tuberculosis* as potential drug target"; by Tamer Samir (June 2013).

2. "Characterization of KdpD and KdpE two component system of *Acinetobacter baumannii* and its role in physiology and pathogenesis"; by Reham Samir (July 2013).
3. "Phenotypic and molecular characterization of multidrug-resistant *Acinetobacter baumannii* isolated from hospitalized patients"; by Mahmoud Abd El-Aty (April 2014).
4. "Study on the possible effect of mangiferin and angiotensin II receptor blockers (ARB) on peptic ulcers caused by reperfusion in rats"; (*in collaboration with the Department of Pharmacology*) by Magdy Awny (September 2015).
5. "Potential Antidiabetic effect of galantamine, a known centrally acting drug, with and without vildagliptin in Type II diabetic rats"; (*in collaboration with the Department of Pharmacology*) by Mennat Allah Ismail (November 2015).
6. "Comparative Study of the anti-inflammatory effect of galantamine and leflunomide with emphasis on the potential mechanism(s) of action of galantamine in experimental adjuvant-induced arthritis in rats"; (*in collaboration with the Department of Pharmacology*) by Mennatallah Adel Gowayed (November 2015).
7. "The Possible Mechanisms of the Cardioprotective Effect of Sitagliptin-a Dipeptidyl Peptidase 4 Inhibitor- In Experimentally Induced Coronary Ischemia-Reperfusion Injury in Male Wistar Rats by Samah Abass (*in collaboration with the Department of Pharmacology*). (June 2016).
8. "Investigating the combined effect of Hepatitis C viral infection and the genetic polymorphisms on the adverse events of methotrexate and 6-mercaptopurine in childhood acute lymphoblastic leukemia"; by Doaa Hamed (*in collaboration with the Department of Clinical Pharmacy*). (June 2016).
9. "Study on keratinase production and keratin degradation by environmental microbial strains isolated from natural keratinaceous material (feather) in Egypt"; by El-Tahir Ahmed (July 2016).
10. "Investigation of the relation between colistin resistance and the expression of *Acinetobacter baumannii* virulence factors"; by Nashwa Ezz-el-arab (*in collaboration with Department of Clinical Pathology, Faculty of Medicine, Cairo University*). (Nov 2016).
11. "Characterization of the type II secretion system T2SS in *Acinetobacter baumannii* and its potential role in virulence"; by Noha Elhosseiny (November 2016).
12. "Characterization of *Moraxella catarrhalis* ABC transporter (s) with potential regulatory repeat elements"; by Yosra Nagy (July 2017).
13. "Tracing the clonal relationships and the detection of a newly identified virulence factor among *Acinetobacter baumannii* strains isolated from Egypt"; by Miran Elfarr (November 2019).
14. "Optimization of Lysostaphin Production and Purification and its Applications to Circumvent Staphylococcal Infections"; by Hanzada Noureldin (June 2020).

15. "A novel kit for rapid and low-cost detection of *Staphylococcus aureus* causing neonatal sepsis"; by Sally Atef (March 2021).
16. "Molecular characterization of carbapenemases in lactose fermenters Enterobacteriaceae isolates from cancer patients in Egypt"; by Dina Ossama (July 2021).
17. "Studying the anti-virulence effect of indole and its derivatives produced by soil bacteria"; by Mai Abdel Wahed (August 2021)

ii- Master's thesis projects:

1. "Microbiological and molecular studies of TEM β -lactamase among clinical isolates of *Klebsiella pneumoniae*"; by Dalia Marzouk (November 2009).
2. "Characterization of *Bacillus cereus* and *Staphylococcus aureus* in food and food products retailed in the Egyptian Market"; by Tamer El-Habibi (January 2012).
3. "Optimization of expression of Hepatitis B surface antigen gene in microbial cells"; by Mohamed Elghanam (October 2012).
4. "A study on the association between quinolones/fluoroquinolones resistance and virulence factors in *Escherichia coli* isolates" by Dina Ossama (July 2013).
5. "Investigating the role of the universal stress protein A in the virulence of *Acinetobacter baumannii*"; by Noha Elhosseiny (October 2013).
6. "Characterization of oxidoreductases produced by bacterial species isolated from the Egyptian environment" by Mohamed Habib (July 2014).
7. "A study of the role of interaction between *Moraxella catarrhalis* surface antigens and the specific host antibody response on the occurrence of otitis media" by Sally Atef (March 2015).
8. "Potential neuroprotective effect of gangliosides in global cerebral ischemia reperfusion in rats"; (*in collaboration with the Department of Pharmacology*) by Aly Chokry (September 2015).
9. "Characterization of post-operative enteric Gram-negative infections following open heart surgeries"; by Ola Sherif (October 2015).
10. "Preliminary characterization of stress regulon in the opportunistic pathogen *Staphylococcus epidermidis*"; by Shahira Elbanna (November 2015).
11. "Design and testing of a novel peptide vaccine against the mucosal pathogen *Moraxella catarrhalis* with emphasis on protecting chronic obstructive pulmonary disease patients from exacerbations"; by Gehad Mohsen (January 2016).

12. "The effect of the α 1-antitrypsin genotype and bacterial loads on the treatment response of Egyptian COPD patients"; by Marwa Elhenawy (*in collaboration with the Department of Clinical Pharmacy*) (June 2016).
13. "Assessment of bacterial virulence in chronic supportive otitis media"; by Shimaa El-Mansour (August 2016).
14. "In silico and in vivo analyses of *Acinetobacter baumannii* outer membrane proteins in a quest for good vaccine candidate" by Mostafa Nawar (August 2016).
15. "Impact of vitamin D deficiency and CYP27B1 SNP on therapeutic response to PEG/INF-RBV in Egyptian patients with chronic Hepatitis C"; by Ahmed Kamel (*in collaboration with the Department of Clinical Pharmacy*). (May 2017).
16. "Screening and evaluation of chemically synthesized anti-virulence compounds as non-conventional Antimicrobial Agents against *Staphylococcus aureus*"; By Norhan H. Mahdely. (January 2018).
17. "Comparison of glycosylated and non-glycosylated granulocyte colony stimulating factors as host defense improving agents during infection"; by Doaa Abd El Rady. (February 2018).
18. "Studying the effect of microbial infections on the molecular actions of therapeutic monoclonal antibodies on certain tissue culture cell lines"; by Mai Allam (July 2018).
19. "Studying the relation between the peptide chain release factor methyltransferase PrmC and the pathogenicity of *Acinetobacter baumannii*"; by Ethar Amin (September 2018).
20. "Preliminary investigation of *Staphylococcus epidermidis* exo-proteome in quest for diagnostic targets"; by Dina Mostafa (February 2021)
21. "Investigating the safety, efficacy of rifaximine antibiotic and its microbial resistance as a secondary prophylaxis of hepatic encephalopathy in Egyptian patients"; by Mai Abd El Monem Abd Rabou (August 2021)

B) Ongoing thesis projects:

i- Ph.D. thesis projects:

1. "Development of a rapid test based on the HCV core protein to be used for monitoring infection"; by Noha Ramadan.
2. "Characterization of the S-formylglutathione hydrolase and its role in the phenotypic characteristics of *Moraxella catarrhalis*"; by Dina Othman.

3. "Investigating the role of the energy-dependent translational throttle A (EttA) protein in *Acinetobacter baumannii* pathogenesis and possible interaction with calpain in lung cell death"; Gehad Yassin.
4. "Exploring the Egyptian natural resources for conventional and unconventional antimicrobial agents against *Acinetobacter baumannii*"; by Norhan Mahdally.
5. "Molecular characterization of one or more of the substrates secreted through type 2 secretion system in *Acinetobacter baumannii*"; by Akram Al-Ahmar.
6. "Screening and characterization of potential modulators of the effectors produced by selected members of the oral microbiota"; by Dina Mostafa.

ii- Master's thesis projects:

1. "A study to evaluate cell wall surface anchor family protein [SLUG_02990; SIsF] of *Staphylococcus lugdunensis* as a vaccine candidate"; by Raghda Killany.
2. "Evaluation of an outer membrane vesicles based-vaccine against *Serratia marcescens*"; by Eman Abdelbaset.
3. "Investigating polymicrobial infections involving *Acinetobacter baumannii* in some Egyptian hospitals"; by Doaa Alaa Eldin.
4. "Deploying nutritional immunity to fight *Acinetobacter baumannii* infections associated with obesity and hyperlipidemia"; by Walaa Gamal.
5. "Screening and characterization of microbial soil isolates collected from the Northeastern regions of Egypt for the production of potential conventional and non-conventional antimicrobial agents against *Acinetobacter baumannii*"; by Ahmed Shawky.
6. "Screening of microbial soil isolates collected from the northeastern regions of Egypt for the production of potential antimicrobial agents against *Staphylococcus aureus*"; by Eman Mamdouh.
7. "Screening a library of Egyptian microbial soil isolates for potential growth and iron-acquisition inhibitors in highly antibiotic-resistant pathogens" by Sara Elbendary.
8. "A comparative study of the gingival bacterial community among smokers and non-smokers with periodontitis in Egypt" by Esraa Ashraf.
9. "In vitro and in vivo characterization of an Alkoxy-phenyl aminoguanidine compounds series for antimicrobial activity against methicillin-resistant *Staphylococcus aureus*" by Nazek Fayed.
10. "The Role of FCG2A, FCG3A Genetic Polymorphisms in the Response to Rituximab treatment in the Egyptian Patient's with Non-Hodgkin's Lymphoma" by Sara Sayed.

XI- Editor and reviewer activities:

- 1- Associate Editor (July 2022-current) in Frontiers in Cellular and Infection Microbiology (Molecular Bacterial Pathogenesis Section)**
 - ISSN: 2235-2988
 - An international peer-reviewed journal published by Frontiers Media SA, Switzerland (<https://www.frontiersin.org/journals/cellular-and-infection-microbiology/editors>)
- 2- Associate Editor (March 2022-current) in Frontiers in Immunology (Microbial Immunology Section)**
 - ISSN: 1664-3224
 - An international peer-reviewed journal published by Frontiers Media SA, Switzerland (<https://www.frontiersin.org/journals/immunology/editors>)
- 3- Associate Editor (March 2022-current) in Frontiers in Microbiology (Microbial Immunology Section)**
 - ISSN: 1664-302X (Microbiology)
 - An international peer-reviewed journal published by Frontiers Media SA, Switzerland (<https://www.frontiersin.org/journals/microbiology/editors>)
- 4- Managing Editor (October 2016-current) in the Bulletin of Faculty of Pharmacy, Cairo University**
 - ISSN: 1110-0931
 - The official journal of Faculty of Pharmacy, Cairo University (<https://www.bfopcu.eg.net/journal/editorialboard.html>)
- 5- Editor-in Chief (May 2010-current) of Archives of Clinical Microbiology**
 - ISSN: 1989-8436
 - An international peer-reviewed journal published by Insight Medical Publishing (iMedPub), USA (<http://www.acmicrob.com/editors.php>).
- 6- Member of the reviewers' panel of the Egyptian Supreme Council of Universities** (Permanent committee for the promotion of Professors and Assistant Professors in the specialty of "Pharmaceutical Microbiology and Immunology") (2014-2022).
- 7- Ad hoc reviewer** for the following international peer-reviewed journals (<https://publons.com/researcher/318918/ahmed-s-attia/peer-review/>):

	Journal	Publisher	Reviews
1.	African Journal of Infectious Diseases	African Journals Online	(1)
2.	Anaerobe	Elsevier	(3)
3.	Annals of Pharmacotherapy	SAGE Publishing	(1)
4.	Antibiotics (Basel)	MDPI	(3)
5.	Bioengineered	Taylor & Francis	(3)
6.	Biologicals	Elsevier	(1)
7.	Biology	MDPI	(2)
8.	Biomolecules	MDPI	(1)

	Journal	Publisher	Reviews
9.	Children	MDPI	(2)
10.	Current Drug Metabolism	Bentham Science Publishers	(4)
11.	Current Medicinal Chemistry	Bentham Science Publishers	(1)
12.	Current Microbiology	Springer	(1)
13.	Expert Opinion on Therapeutic Targets	Informa	(1)
14.	Frontiers in Cellular and Infection Microbiology	Frontiers	(1)
15.	Infection and Drug Resistance	Dove Medical Press	(3)
16.	Infection and Immunity	American Society for Microbiology	(10)
17.	Infection, Genetics and Evolution	Elsevier	(1)
18.	International Journal of Molecular Sciences	MDPI	(1)
19.	Journal of Advanced Research	Elsevier	(1)
20.	Journal of Clinical Microbiology	American Society for Microbiology	(6)
21.	Journal of Genetic Engineering and Biotechnology	Springer	(1)
22.	Journal of Infection in Developing Countries	Open Learning on Enteric Pathogens (Italy)	(7)
23.	Journal of Natural Science, Biology and Medicine	Wolters Kluwer Medknow Publications	(1)
24.	Journal of Pharmacy Technology	SAGE Publishing	(1)
25.	Journal of Proteomics	Elsevier	(2)
26.	Letters in Applied Microbiology	Wiley	(1)
27.	Life Sciences	Elsevier	(4)
28.	Molecular Immunology	Elsevier	(3)
29.	mSphere	American Society for Microbiology	(1)
30.	OMICS: A Journal of Integrative Biology	Mary Ann Liebert.	(2)
31.	Pathogens and Disease	Oxford University Press	(1)
32.	PeerJ	PeerJ Inc.	(2)
33.	PLoS One	Public Library of Science	(5)
34.	Research in Veterinary Science	Elsevier	(6)
35.	Respiratory Research	BioMed Central Ltd.	(8)
36.	Saudi Journal of Biological Sciences	King Saud University	(1)
37.	Scientific Reports	Nature	(1)

	Journal	Publisher	Reviews
38.	The Journal of Basic and Applied Zoology	Springer	(2)
39.	Therapeutic Advances in Chronic Disease	SAGE	(1)
40.	Virulence	Taylor & Francis	(3)
41.	World Journal of Microbiology and Biotechnology	Springer	(14)

XII- List of publications:

a- Author's metrics:

	<u>Scopus</u>	<u>Google Scholar</u>
h-index	17	19
Total citations	938	1349
Link	https://www.scopus.com/authorid/detail.uri?authorId=10045208200	https://scholar.google.com/citations?user=pETEZzQAAAAJ&hl=en&oi=ao

b- Publications:

1. Amer MA, Ramadan MA, **Attia AS**, Wasfi R. Silicone Foley catheters impregnated with microbial indole derivatives inhibit crystalline biofilm formation by *Proteus mirabilis*. *Frontiers in Cellular and Infection Microbiology* 2022;12:1010625.
2. Saad MA, Eissa NM, Ahmed MA, ElMeshad AN, Laible G, **Attia AS**, et al. Nanoformulated Recombinant Human Myelin Basic Protein and Rituximab Modulate Neuronal Perturbations in Experimental Autoimmune Encephalomyelitis in Mice. *International Journal of Nanomedicine*. 2022;17:3967-87.
3. Elsebaie MM, El-Din HTN, Abutaleb NS, Abuelkhir AA, Liang H-W, **Attia AS**, et al. Exploring the structure-activity relationships of diphenylurea as an antibacterial scaffold active against methicillin-and vancomycin-resistant *Staphylococcus aureus*. *European Journal of Medicinal Chemistry*. 2022:114204.
4. Abdel Moneim M, Abdelaziz DH, Ibrahim Nagy Y, Abdel Baki A, **Attia AS**, Sabry N. Rifaximin microbial resistance and its efficacy and safety as a secondary prophylaxis of hepatic encephalopathy in patients with hepatitis C virus-related cirrhosis. *International Journal of Clinical Practice*. 2021:e14807.
5. Elhosseiny NM, Samir TM, Ali AA, El-Kholy AA, **Attia AS**. Development of an Immunochromatographic Strip Using Conjugated Gold Nanoparticles for the Rapid Detection of *Klebsiella pneumoniae* Causing Neonatal Sepsis. *Pharmaceutics*. 2021;8(8):1141.

6. Mahdally NH, George RF, Kashef MT, Al-Ghobashy M, Murad FE, **Attia AS**. Staquorsin: A Novel *Staphylococcus aureus* Agr-Mediated Quorum Sensing Inhibitor Impairing Virulence in vivo Without Notable Resistance Development. *Frontiers in Microbiology*. 2021;12:700494.
7. Rizk SS, Elwakil WH, **Attia AS**. Antibiotic-Resistant *Acinetobacter baumannii* in Low-Income Countries (2000-2020): Twenty-One Years and Still below the Radar, Is It Not There or Can They Not Afford to Look for It? *Antibiotics (Basel)*. 2021;10(7).
8. Amer MA, Wasfi R, **Attia AS**, Ramadan MA. Indole Derivatives Obtained from Egyptian *Enterobacter* sp. Soil Isolates Exhibit Antivirulence Activities against Uropathogenic *Proteus mirabilis*. *Antibiotics (Basel)*. 2021;10(4):363.
9. Osama D, El-Mahallawy H, Mansour MT, Hashem A, **Attia AS**. Molecular Characterization of Carbapenemase-Producing *Klebsiella pneumoniae* Isolated from Egyptian Pediatric Cancer Patients Including a Strain with a Rare Gene-Combination of beta-Lactamases. *Infection and Drug Resistance*. 2021;14:335-48.
10. Mohamed SA, Samir TM, Helmy OM, Elhosseiny NM, Ali AA, El-Kholy AA, **Attia AS**. A Novel Surface-Exposed Polypeptide Is Successfully Employed as a Target for Developing a Prototype One-Step Immunochromatographic Strip for Specific and Sensitive Direct Detection of *Staphylococcus aureus* Causing Neonatal Sepsis. *Biomolecules*. 2020;10(11).
11. Hagra M, Abutaleb NS, Elhosseiny NM, Abdelghany TM, Omara M, Elsebaei MM, Alhashimi M, Norvil AB, Gutay MI, Gowher H, **Attia AS**, Seleem MN, Mayhoub AS. Development of Biphenylthiazoles Exhibiting Improved Pharmacokinetics and Potent Activity Against Intracellular *Staphylococcus aureus*. *ACS Infectious Diseases*. 2020;6(11):2887-900.
12. Elhosseiny NM, Elhezawy NB, Sayed RM, Khattab MS, El Far MY, **Attia AS**. Gamma-Glutamyltransferase as a Novel Virulence Factor of *Acinetobacter baumannii* Inducing Alveolar Wall Destruction and Renal Damage in Systemic Disease. *The Journal of Infectious Diseases*. 2020;222(5):871-9.
13. Nour El-Din HT, Elhosseiny NM, El-Gendy MA, Mahmoud AA, Hussein MM, **Attia AS**. A Rapid Lysostaphin Production Approach and a Convenient Novel Lysostaphin Loaded Nano-emulgel; As a Sustainable Low-Cost Methicillin-Resistant *Staphylococcus aureus* Combating Platform. *Biomolecules*. 2020;10(3):435.
14. Gowayed MA, Rothe K, Rossol M, **Attia AS**, Wagner U, Baerwald C, El-Abhar HS, Refaat R. The role of alpha7nAChR in controlling the anti-inflammatory/anti-arthritic action of galantamine. *Biochemical Pharmacology*. 2019;170:113665.
15. El Far MY, El-Mahallawy HA, **Attia AS**. Tracing the dissemination of the international clones of multidrug-resistant *Acinetobacter baumannii* among cancer patients in Egypt using the PCR-based open reading frame typing (POT) method. *Journal of Global Antimicrobial Resistance*. 2019;19:210-5.

16. Choucry AM, Al-Shorbagy MY, **Attia AS**, El-Abhar HS. Pharmacological Manipulation of Trk, p75NTR, and NGF Balance Restores Memory Deficit in Global Ischemia/Reperfusion Model in Rats. *Journal of Molecular Neuroscience*. 2019;68(1):78-90.
17. Elhosseiny NM, Elhezawy NB, **Attia AS**. Comparative proteomics analyses of *Acinetobacter baumannii* strains ATCC 17978 and AB5075 reveal the differential role of type II secretion system secretomes in lung colonization and ciprofloxacin resistance. *Microbial Pathogenesis*. 2019;128:20-7.
18. Elhosseiny NM, **Attia AS**. *Acinetobacter*: an emerging pathogen with a versatile secretome. *Emerging Microbes & Infections*. 2018;7(1):33.
19. Kamel AM, Farid SF, **Attia AS**, El Raziky M. Association of vitamin D binding protein polymorphisms with response to therapy in Egyptian chronic hepatitis C patients. *Journal of Infection in Developing Countries*. 2017;11(10):781-90.
20. Nagy YI, Hussein MMM, Ragab YM, **Attia AS**. Isogenic mutations in the *Moraxella catarrhalis* CydDC system display pleiotropic phenotypes and reveal the role of a palindrome sequence in its transcriptional regulation. *Microbiological Research*. 2017;202:71-9.
21. Samir R, Hussein SH, Elhosseiny NM, Khattab MS, Shawky AE, **Attia AS**. Adaptation to Potassium-Limitation Is Essential for *Acinetobacter baumannii* Pneumonia Pathogenesis. *The Journal of Infectious Diseases*. 2016;214(12):2006-13.
22. Elhosseiny NM, El-Tayeb OM, Yassin AS, Lory S, **Attia AS**. The secretome of *Acinetobacter baumannii* ATCC 17978 type II secretion system reveals a novel plasmid encoded phospholipase that could be implicated in lung colonization. *International Journal of Medical Microbiology*. 2016;306(8):633-41.
23. Al-Ghobashy MA, Hassan SA, Abdelaziz DH, Elhosseiny NM, Sabry NA, **Attia AS**, El-Sayed MH. Development and validation of LC-MS/MS assay for the simultaneous determination of methotrexate, 6-mercaptopurine and its active metabolite 6-thioguanine in plasma of children with acute lymphoblastic leukemia: Correlation with genetic polymorphism. *Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences*. 2016;1038:88-94.
24. Hennawy MG, Elhosseiny NM, Sultan H, Abdelfattah W, Akl Y, Sabry NA, **Attia AS**. The effect of alpha1-antitrypsin deficiency combined with increased bacterial loads on chronic obstructive pulmonary disease pharmacotherapy: A prospective, parallel, controlled pilot study. *Journal of Advanced Research*. 2016;7(6):1019-28.
25. Abdelaziz DH, Elhosseiny NM, Khaleel SA, Sabry NA, **Attia AS**, El-Sayed MH. Association Between Combined Presence of Hepatitis C Virus and Polymorphisms in Different Genes With Toxicities of Methotrexate and 6-Mercaptopurine in Children With Acute Lymphoblastic Leukemia. *Pediatric Blood & Cancer*. 2016;63(9):1539-45.
26. **Attia AS**. Accurate diagnosis is paving the road to better clinical outcomes (Editorial). *Archives of Clinical Microbiology*. 2016;7(4):e008.

27. Yassin GM, Amin MA, **Attia AS**. Immunoinformatics Identifies a Lactoferrin Binding Protein A Peptide as a Promising Vaccine With a Global Protective Prospective Against *Moraxella catarrhalis*. The Journal of Infectious Diseases. 2016;213(12):1938-45.
28. Ali MA, El-Abhar HS, Kamel MA, **Attia AS**. Antidiabetic Effect of Galantamine: Novel Effect for a Known Centrally Acting Drug. PloS One. 2015;10(8):e0134648.
29. Sabiel EA, Abdel-fattah AM, Nashy EHA, Hussein MM, **Attia AS**. Novel Keratinase Enzyme from *Cyberlindnera fabianii* NRC3 Aza with Promising Keratin-Biodegradation and Hide-Dehairing Activities. Journal of Indian Leather Technologists' Association. 2015;65(8):17-25.
30. Mahmoud-Awny M, **Attia AS**, Abd-Ellah MF, El-Abhar HS. Mangiferin Mitigates Gastric Ulcer in Ischemia/ Reperfused Rats: Involvement of PPAR-gamma, NF-kappaB and Nrf2/HO-1 Signaling Pathways. PloS One. 2015;10(7):e0132497.
31. Abdel-fattah AM, Nashy E-SH, Sabiel E-TA, Hussien MM, **Attia AS**. Novel Keratinolytic Activity of *Cyberlindnera fabianii* Nrc3 Aza as A Plant Growth Promoting Agent (PGPA). International Journal of Applied Sciences and Biotechnology. 2015;3(4):609-18.
32. Elfaky MA, Yassien MA, **Attia AS**, Mansy MS, Ashour MS. Antimicrobial resistance pattern of biofilm forming *Pseudomonas aeruginosa* isolated from patients with nasogastric and endotracheal tubes. World Journal of Pharmaceutical Sciences. 2015;3(3):401-6.
33. Elhosseiny NM, Amin MA, Yassin AS, **Attia AS**. *Acinetobacter baumannii* universal stress protein A plays a pivotal role in stress response and is essential for pneumonia and sepsis pathogenesis. International Journal of Medical Microbiology. 2015;305(1):114-23.
34. Joslin SN, Pybus C, Labandeira-Rey M, Evans AS, **Attia AS**, Brautigam CA, Hansen EJ. A *Moraxella catarrhalis* two-component signal transduction system necessary for growth in liquid media affects production of two lysozyme inhibitors. Infection and Immunity. 2015;83(1):146-60.
35. Khalil MA, Azzazy HM, **Attia AS**, Hashem AG. A sensitive colorimetric assay for identification of *Acinetobacter baumannii* using unmodified gold nanoparticles. Journal of Applied Microbiology. 2014;117(2):465-71.
36. Elfaky MA, Yassien MA, **Attia AS**, Mansy MS, Ashour MS. Microbiological studies on resistance patterns of antimicrobial agents among Gram negative respiratory tract pathogens. African Journal of Microbiology Research 2014;8(27):2583-91.
37. Fouad M, **Attia AS**, Tawakkol WM, Hashem AM. Emergence of carbapenem-resistant *Acinetobacter baumannii* harboring the OXA-23 carbapenemase in intensive care units of Egyptian hospitals. International Journal of Infectious Diseases. 2013;17(12):e1252-4.

38. **Attia AS**, Cassat JE, Aranmolate SO, Zimmerman LJ, Boyd KL, Skaar EP. Analysis of the *Staphylococcus aureus* abscess proteome identifies antimicrobial host proteins and bacterial stress responses at the host-pathogen interface. *Pathogens and Disease*. 2013;69(1):36-48.
39. Wakeman CA, Hammer ND, Stauff DL, **Attia AS**, Anzaldi LL, Dikalov SI, Calcutt MW, Skaar EP. Menaquinone biosynthesis potentiates haem toxicity in *Staphylococcus aureus*. *Molecular Microbiology*. 2012;86(6):1376-92.
40. **Attia AS**, Schroeder KA, Seeley EH, Wilson KJ, Hammer ND, Colvin DC, Manier ML, Nicklay JJ, Rose KL, Gore JC, Caprioli RM, Skaar EP. Monitoring the inflammatory response to infection through the integration of MALDI IMS and MRI. *Cell Host & Microbe*. 2012;11(6):664-73.
41. Elghanam MS, **Attia AS**, Shoeb HA, Hashem AE. Expression and purification of hepatitis B surface antigen S from *Escherichia coli*; a new simple method. *BMC Research Notes*. 2012;5:125.
42. Elhabibi TM, **Attia AS**, Hashem AM, Ashour MS. Characterization of *Bacillus cereus* and *Staphylococcus aureus* strains isolated from food and food products retailed in the Egyptian Markets. *New Egyptian Journal of Microbiology*. 2012;31:40-52.
43. **Attia AS**. Archives of Clinical Microbiology: New Vision (Editorial). *Archives of Clinical Microbiology*. 2010;1(2):1.
44. Torres VJ, **Attia AS**, Mason WJ, Hood MI, Corbin BD, Beasley FC, Anderson KL, Stauff DL, McDonald WH, Zimmerman LJ, Friedman DB, Heinrichs DE, Dunman PM, Skaar EP. *Staphylococcus aureus* Fur regulates the expression of virulence factors that contribute to the pathogenesis of pneumonia. *Infection and Immunity*. 2010;78(4):1618-28.
45. **Attia AS**, Benson MA, Stauff DL, Torres VJ, Skaar EP. Membrane damage elicits an immunomodulatory program in *Staphylococcus aureus*. *PLoS Pathogens*. 2010;6(3):e1000802.
46. **Attia AS**, Sedillo JL, Hoopman TC, Liu W, Liu L, Brautigam CA, Hansen EJ. Identification of a bacteriocin and its cognate immunity factor expressed by *Moraxella catarrhalis*. *BMC Microbiology*. 2009;9:207.
47. Marzouk DS, **Attia AS**, Hamouda HM, Hashem AM, Shoeb HA. Comparative study of TEM & SHV β -lactamase genes in *Klebsiella pneumoniae* isolates. *Egyptian Journal of Biomedical Sciences*. 2009;29:299-309.
48. Brooks MJ, Sedillo JL, Wagner N, Laurence CA, Wang W, **Attia AS**, Hansen EJ, Gray-Owen SD. Modular arrangement of allelic variants explains the divergence in *Moraxella catarrhalis* UspA protein function. *Infection and Immunity*. 2008;76(11):5330-40.
49. Brooks MJ, Sedillo JL, Wagner N, Wang W, **Attia AS**, Wong H, Laurence CA, Hansen EJ, Gray-Owen SD. *Moraxella catarrhalis* binding to host cellular receptors is

mediated by sequence-specific determinants not conserved among all UspA1 protein variants. *Infection and Immunity*. 2008;76(11):5322-9.

50. **Attia AS**, Sedillo JL, Wang W, Liu W, Brautigam CA, Winkler W, Hansen EJ. *Moraxella catarrhalis* expresses an unusual Hfq protein. *Infection and Immunity*. 2008;76(6):2520-30.

51. Wang W, Pearson MM, **Attia AS**, Blick RJ, Hansen EJ. A UspA2H-negative variant of *Moraxella catarrhalis* strain O46E has a deletion in a homopolymeric nucleotide repeat common to *uspA2H* genes. *Infection and Immunity*. 2007;75(4):2035-45.

52. **Attia AS**, Hansen EJ. A conserved tetranucleotide repeat is necessary for wild-type expression of the *Moraxella catarrhalis* UspA2 protein. *Journal of Bacteriology*. 2006;188(22):7840-52.

53. **Attia AS**, Ram S, Rice PA, Hansen EJ. Binding of vitronectin by the *Moraxella catarrhalis* UspA2 protein interferes with late stages of the complement cascade. *Infection and Immunity*. 2006;74(3):1597-611.

54. Wang W, **Attia AS**, Liu L, Rosche T, Wagner NJ, Hansen EJ. Development of a shuttle vector for *Moraxella catarrhalis*. *Plasmid*. 2006;55(1):50-7.

55. **Attia AS**, Lafontaine ER, Latimer JL, Aebi C, Syrogiannopoulos GA, Hansen EJ. The UspA2 protein of *Moraxella catarrhalis* is directly involved in the expression of serum resistance. *Infection and Immunity*. 2005;73(4):2400-10.

56. Salama AA, Hosny AMS, Ahmady AM, Abdel-Hamid AA, **Hussein ASM**. Susceptibility of certain nosocomial pathogens to certain antibiotics and biocides commonly used in Egyptian hospitals. *New Egyptian Journal of Microbiology*. 2004;8:274-99.

XIII- Presentations:

A- Oral presentations:

1. Oral presenter in the American Society for Microbiology online Webinar. August 2021. Title of the talk: "Point-of-Care (POC) microbial diagnostics current situation and future perspectives".
2. Oral presenter in the Newgiza University Biologics and Biosimilars Symposium. Giza, Egypt. March 2020. Title of the talk: " Industry – academia collaboration for Trastuzumab characterization Biological Assessment".
3. Oral presenter in the 7th Arab-American Frontiers of Science, Engineering, and Medicine Symposium. Cairo, Egypt. November 2019. Title of the talk: " Employing cutting-edge technologies to fight the erosion of our antimicrobial arsenal".
4. Oral presenter in the National Committee for Microbiological Sciences workshop " Antimicrobial Resistance threat: Time to act". Cairo, Egypt. March 2019. Title of

the talk: "Non-conventional approaches to overcome the erosion of our antimicrobial arsenal"

5. Oral presenter in the 6th International Conference for Tropical and Infectious Diseases. Barcelona, Spain. January 2019. Title of the talk: " Development of a novel rapid assay for the detection of *Enterobacter cloacae* using conjugated gold nano-particles".
6. Oral presenter in the Al-Azhar 5th International Conference of Pharmaceutical Sciences and Drug Industries. Hurghada, Egypt. September 2017. Title of the talk: "Innovative approaches for combating bacterial infections".
7. Oral presenter in the 8th Faculty of Pharmacy Cairo University International Conference. Cairo, Egypt. April 2017. Title of the talk: "Diploma of genomics & bioinformatics: documentary".
8. Oral presenter in the 7th Faculty of Pharmacy Cairo University International Conference. Cairo, Egypt. April 2016. Title of the talk: "Looking outside the box to find novel antimicrobials that can survive longer in the market".
9. Oral presenter in the Department of Microbiology & Immunology Scientific Conference. Cairo, Egypt. May 2015. Title of the talk: "Chasing the enemy at the battlefield and behind the frontlines".
10. Oral presenter in the 6th Faculty of Pharmacy Cairo University International Conference. Cairo, Egypt. April 2015. Title of the talk: "Combined Effect of Host Genetic Polymorphisms and HCV Infection on the Therapeutic Outcome of Acute Lymphoblastic Leukemia".
11. Oral presenter in the 3rd FUE International Conference of Pharmaceutical Sciences. Cairo, Egypt. February 2015. Title of the talk: "Bacterial Secretome; Secrets and Potentials".
12. Oral presenter in the 2nd International Conference on Biotechnology and Environmental Safety, organized by the National Research Centre, Giza Egypt. May 2014. Title of the talk: "Merging Medical Informatics and Biotechnology to Design a Global *Acinetobacter baumannii* Vaccine".
13. Oral presenter in the 5th Faculty of Pharmacy Cairo University International Conference. Cairo, Egypt. April 2014. Title of the talk: "Cutting-edge technologies and molecular approaches for exploring microbial targets in quest for new antimicrobials".
14. Oral presentation in the 58th International Meeting of the Egyptian Society of Clinical Chemistry, Cairo, Egypt. November 2013. Title of the talk: "Molecular and

Genetic Approaches for Exploring Microbial Virulence in Quest for Novel Therapeutic Targets”

15. Oral presenter in the 4th Faculty of Pharmacy Cairo University International Conference. Cairo, Egypt. April 2013. Title of the talk: “Studying the Effect of the Combination of Pharmacogenomics and Infectious Agents on Therapeutic Outcomes in Egyptian Patients”.
16. Oral presenter in the 3rd Health IT & mHealth Innovations Conference. Cairo, Egypt. April 2012. Title of the talk: “Health informatics along the road from lab bench to bedside”.
17. Oral presenter in the 55th International Scientific Meeting of The Egyptian Society of Clinical Chemistry, Cairo, Egypt. January 2008. Title of the talk: “Governance of Synthetic Microorganisms: Now or Later?”
18. Oral presenter in the workshop “Recent Advances in Biotechnology and Clinical Pharmacy”, Cairo, Egypt. November 2007. Title of the talk: “The UspA2 protein and serum resistance of *Moraxella catarrhalis*”.

B- Poster presentations:

1. Poster presenter in the 2nd Re-entering Antibacterial Drug Development Summit, Boston, USA. November 2015. Title of the poster: “Development of a Novel System to Produce and Purify Lysostaphin and Its Use as an Economic Tool for Fighting Staphylococcal Infections”.
2. Poster presenter in the 114th General Meeting of the American Society for Microbiology, Boston, USA. May 2014. Title of the poster: “Development and Optimization of a Simple and Economic System for the Screening of Mycobacterial Isocitrate Lyase Inhibitors”.
3. Poster presenter in the 7th International Biometals Symposium. Tucson, Arizona, USA. July 2010. Title of the poster: “Heme-toxicity in *Staphylococcus aureus* is relieved by exporting S-adenosyl-L-homocysteine”
4. Poster presenter in the 5th International Conference on Gram-Positive Microorganisms, San Diego, California, USA. June 2009. Title of the poster: “Membrane damage elicits an immunomodulatory program in *Staphylococcus aureus*”.
5. Poster presenter in the 106th General Meeting of the American Society for Microbiology, Orlando, Florida. May 2006. Title of the Poster: "A conserved tetranucleotide repeat is necessary for wild-type expression of the *Moraxella catarrhalis uspA2* gene ".

6. Poster presenter in the 105th General Meeting of the American Society for Microbiology, Atlanta, Georgia. June 2005. Title of the Poster: "Serum resistance and the interaction of *Moraxella catarrhalis* with C4BP and vitronectin".
7. Poster presenter in the 104th General Meeting of the American Society for Microbiology, New Orleans, Louisiana. May 2004. Title of the Poster: "The UspA2 protein of *Moraxella catarrhalis* is directly involved in the expression of serum resistance".

C. Principal investigator on presentations by supervised students

1. Oral presentation in the Acinetobacter2020 virtual symposium organized Mario Feldman and Charles Van der Henst via Zoom. May 2020. Title of the talk: "Gamma-glutamyl transferase is a novel virulence factor of *Acinetobacter baumannii* that induces alveolar wall destruction and renal damage in systemic pathology" Presented by Noha Elhosseiny.
2. Oral presentation in the Newgiza University Biologics and Biosimilars Symposium. Giza, Egypt. March 2020. Title of the talk: "Saving young lives: Immunogold strips for rapid and low-cost diagnosis of neonatal sepsis" Presented by Noha Elhosseiny.
3. Oral presentation in the 5th FUE International Conference of Pharmaceutical Sciences. Cairo, Egypt. January 2019. Title of the talk: "Optimization of the Production and Purification of Both Native and Recombinant Anti-staphylococcal Lysostaphin." Presented by Hanzada Noureldin.
4. Poster presentation in the 5th FUE International Conference of Pharmaceutical Sciences. Cairo, Egypt. January 2019. Title of the poster: "Preliminary Investigation of the *Staphylococcus epidermidis* Exo-proteome in Quest for Diagnostic Targets." Presented by Dina Mostafa.
5. Poster presentation in the German University in Cairo International Conference. Cairo, Egypt, March 2018. "A study to evaluate a cell wall surface anchor family protein [SLUG_02990; SIsF] of *Staphylococcus lugdunensis* as a vaccine candidate." Presented by Raghda Kilany.
6. Poster presentation in the 8th Faculty of Pharmacy Cairo University international conference. Cairo, Egypt. April 2017. Title of the poster: "Comparison of glycosylated vs. Non-glycosylated granulocyte colony stimulating factors (G-CSF) as host defense improving agents during infection". Presented by Doaa Abd El Rady.

7. Poster presentation in the 4th FUE International Conference of Pharmaceutical Sciences. Cairo, Egypt. February 2017. Title of the poster: "Studying the effect of microbial infections on the molecular actions of therapeutic monoclonal antibodies on tissue culture cell lines". Presented by Mai Allam.
8. Oral presentation in the Middle East Molecular Biology Source Annual Congress, Doha, Qatar. November 2016. Title of the talk: "Immunoinformatics identifies a lactoferrin binding protein A peptide as a promising vaccine with a global protective prospective against *Moraxella catarrhalis*". Presented by Gehad Yassin.
9. Oral presentation in the 2nd Annual Fulbright Alumni Conference Cairo, Egypt. October 2016. Title of the talk: "The secret of what it secretes; analysis of the T2SS-dependent secretome of *Acinetobacter baumannii*". Presented by Noha Elhosseiny.
10. Poster presentation in the 26th European Congress of Clinical Microbiology and Infectious Diseases. Amsterdam, Netherland. April 2016. Title of the poster: "Studying the role of the peptide chain release factor methyltransferase "PrmC" in the pathogenicity of *Acinetobacter baumannii*". Presented by Ethar Amin
11. Poster presentation in the Microbial Stress: from Molecules to Systems, Sitges, Spain. November 2015. Title of the poster: "Effect of pH Shift on the Regulation and Expression of Some Virulence Factors in the Opportunistic Pathogen *S. epidermidis*". Presented by Shahira El-Banna, MSc.
12. Poster presentation in the 6th Faculty of Pharmacy Cairo University international conference. Cairo, Egypt. April 2015. Title of the poster: "Reverse Vaccinology Identifies A Novel Effective Peptide Vaccine Against the Mucosal Pathogen *Moraxella catarrhalis*". Presented by Gehad Yassin.
13. Oral presentation in the 3rd FUE International Conference of Pharmaceutical Sciences. Cairo, Egypt. February 2015. Title of the talk: "Characterization of the BpeE/F-OprC Efflux System in *Acinetobacter baumannii*". Presented by Salma Hussein.
14. Poster presentation in virtual poster symposium of the American Collage of Clinical Pharmacy. May 2014. Title of the poster: "The Effect of α 1-antitrypsin Deficiency and Bacterial Loads on the Efficacy of Chronic Obstructive Pulmonary Disease Pharmacotherapy in Egyptian Patients". Presented by Marwa Elhenawy.
15. Poster presentation in the 114th General Meeting of the American Society for Microbiology, Boston, USA. May 2014. Title of the poster: "*Acinetobacter baumannii* Type Two Secretion System; Unique Genetic Arrangement and Potential Role in Virulence". Presented by Noha Elhosseiny, MSc.

16. Poster presentation in the TWAS/BioVision Alexandria. NXT 2014, Alexandria, Egypt. April 2014. Title of the poster: "Polymorphisms in Genes Encoding Drugs Metabolizing Enzymes among Egyptian Acute Lymphoblastic Leukemia Patients". Presented by Noha Elhosseiny, M.Sc.
17. Poster presentation in the TWAS/BioVision Alexandria. NXT 2014, Alexandria, Egypt. April 2014. Title of the poster: "Genetic and Phenotypic Characterization of *Moraxella catarrhalis* strains isolated from Egyptian otitis media children". Presented by Sally Atef
18. Oral presentation in the Acinetobacter 2013 Meeting, Cologne, Germany. June 2013. Title of the talk: "Designing a Vaccine against *Acinetobacter baumannii* with a Global Perspective". Presented by Mostafa Nawar.
19. Poster presentation in the Acinetobacter 2013 Meeting, Cologne, Germany. June 2013. Title of the poster: "Molecular and Physiological Characterization of the KdpD/E Two-Component System in *Acinetobacter baumannii*". Presented by Reham Samir, M.Sc.
20. Poster presentation in the 113th General Meeting of the American Society for Microbiology, Denver, Colorado, USA. May 2013. Title of the poster: "New, Rapid, Low-Cost System for Expression and Purification of Recombinant Lysostaphin from *Staphylococcus simulans* and its Application to Combat Staphylococcal Biofilms". Presented by Noha Elhosseiny.
21. Poster presentation in the 113th General Meeting of the American Society for Microbiology, Denver, Colorado, USA. May 2013. Title of the poster: "Construction and Characterization of an Isogenic Mutant of the Universal Stress Protein (UspA) in the Emerging Pathogen *Acinetobacter baumannii*". Presented by Noha Elhosseiny.
22. Poster presentation in the 112th General Meeting of the American Society for Microbiology, San Francisco, California, USA. June 2012. Title of the poster: "Designing a vaccine against *Staphylococcus lugdunensis*; keeping the heart in mind". Presented by Noha Elhosseiny.

D. Co-author on a presentation by a colleague or a student

1. Poster presentation in the 20th Dubai International Pharmaceuticals and Technologies Conference (DUPHAT 2015). Dubai, United Arab Emirates. March 2015. Title of the poster: "Assessment of virulence factors in bacterial isolates causing chronic supportive otitis media among Egyptian patients". Presented by Shaimaa Mansour

2. Poster presentation in the 3rd FUE International Conference of Pharmaceutical Sciences. Cairo, Egypt. February 2015. Title of the talk: "Phenotypic and Molecular Characterization of Bacterial Isolates Causing Perioperative Infections Following Open Heart Surgeries in Aswan Heart Center". Presented by Ola Sherif.
3. Poster presentation in the 3rd International Conference on Gram-Positive Pathogens, Omaha, Nebraska, USA. October 2010. Title of the poster: "Exploring the staphylococcal abscess proteome identifies novel host defenses and microbial therapeutic targets". Presented by Indriti Hood, Ph.D.

E. Chairman of a session in a conference

1. Co-chair of the session with the title "The story of Trastuzumab" in the Newgiza University Biologics and Biosimilars Symposium. Giza, Egypt. March 2020.
2. Co-chair of the session with the title "Clinical Pharmacy" in 10th Annual Conference of National Hepatology & Tropical Medicine Research Institute (NHTMRI PEARLS). Cairo, Egypt. September 2018.
3. Co-chair of the session with the title "Microbiology & Biotechnology / Biochemistry & Molecular Biology; Original Research Presentations" in 4th FUE International Conference of Pharmaceutical Sciences. Cairo, Egypt. February 2017.
4. Co-chair of the session with the title "Molecular Microbiology Symposium" in the 58th International Meeting of the Egyptian Society of Clinical Chemistry, Cairo, Egypt. November 2013.

XIV- Funded projects:

A- Running projects:

1. The discovery of antimicrobial agents against the multidrug resistant *Acinetobacter baumannii* from soil-derived microbes. **(2022). Principal Investigator.** British Council (Research Environment Links). **(GBP 49,330.00)**. In collaboration with University of the West of Scotland, UK.
2. The production of nanobodies using the yeast display technology as a non-conventional tool for precision medicine in infective diseases and beyond. **(2020-2022). Principal Investigator.** Academy of Scientific Research and Technology Science and Technology Center (STC). **(EGP 1,597,260)**.
3. Exploring the Egyptian natural resources for conventional and unconventional antimicrobial agents using in-silico, chemical and biological screening. **(2020-2022). Principal Investigator.** Newton-Mosharafa Fund (Institutional Links Grants). **(GBP 260,191.00)**. In collaboration with University of the West of Scotland, UK.

4. Deploying Nutritional Immunity via Chemical and Natural Compounds to Fight *Acinetobacter baumannii* Infections Associated with Obesity and Hyperlipidemia. **(2019-2022), Principal Investigator.** Faculty of Pharmacy Interdisciplinary Research Grant **(EGP 175,000)**. In collaboration with the Departments of Pharmaceutical Chemistry, Pharmacognosy, Pharmacology, Pharmaceutics and Industrial Pharmacy, and Analytical Chemistry.
5. Assessment of biosimilarity and interchangeability of locally produced biopharmaceuticals using statistically-guided orthogonal testing protocols at industrial scale. (2020-2023). **Co-Principal Investigator.** Science, Technology, and Innovation Funding Authority **(EGP 5,106,400)**. In collaboration with Newgiza University and Minapharm Pharmaceuticals.

B- Fulfilled projects:

6. NeoSep-Fast: A novel multiplex kit for rapid and low-cost detection and diagnosis of neonatal sepsis. **(2015-2019), Principal Investigator.** Science and Technological Development Fund **(EGP 652,000)**. In collaboration with the Faculty of Medicine, Cairo University.
7. Formulation and Evaluation of Surface Functionalized Nanoparticles Enclosing Myelin Basic Protein for Treatment of Multiple Sclerosis. **(2016-2019), Co-investigator.** Science and Technological Development Fund **(EGP 600,000)**. In collaboration with National Cancer Institute, American University in Cairo, and SEDICO Pharmaceuticals Company.
8. Identification and Characterization of Synthetic and Naturally Occurring Virulence Inhibitors as Non-conventional Antimicrobial Agents. **(2015-2018), Principal Investigator.** Faculty of Pharmacy Interdisciplinary Research Grant **(EGP 125,000)**. In collaboration with the Departments of Pharmaceutical Chemistry, Pharmacognosy, Pharmacology and Analytical Chemistry.
9. Investigating the Combined Effect of Hepatitis C Viral Infection and the Genetic Polymorphisms on the Adverse Events of Methotrexate and 6-Mercaptopurine in Childhood Acute Lymphoblastic Leukemia. **(2012-2014), Principal Investigator.** Faculty of Pharmacy Interdisciplinary Research Grant **(L.E. 75,000)**. In collaboration with the Departments of Clinical Pharmacy and Analytical Chemistry.
10. Determination of the role of the α 1-antitrypsin genotype and bacterial loads on the treatment response of Egyptian COPD patients. **(2012-2014), Principal Investigator.** Faculty of Pharmacy Interdisciplinary Research Grant **(L.E. 50,000)**. In collaboration with the Department of Clinical Pharmacy.

XV- Workshops and activities organization:

1. Organization of “Molecular Biology Practice BTC002” workshop in coordination with the Biotechnology Center (BTC) in the Faculty of Pharmacy, Cairo University (14th - 19th Sept 2011).
2. Organization of “Molecular Biology Practice BTC003” workshop in coordination with the Biotechnology Center (BTC) in the Faculty of Pharmacy, Cairo University (5th - 9th Feb 2012).
3. Supervising and moderating the “Journal Club” activity in the Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University (10/2010 – 9/2011).

XVI- Membership of Faculty committees:

1. Member of the School of Pharmacy, Newgiza University Council Board from March 2021 till now. Overseeing all the Faculty administrative, education, research, and community services affairs.
2. Member of the Faculty of Pharmacy, Cairo University Council Board from December 2018 to November 2020. Overseeing all the Faculty administrative, education, research, and community services affairs.
3. Member of “The Clinical Pharmacy Program Supervising Committee” from October 2010 to February 2020. Responsible for the administration of the Clinical Pharmacy Program in the Faculty of Pharmacy, Cairo University.
4. Member of the Graduate Students Admission Committee for the Department of Microbiology from July 2014 till now. Responsible for the selection of graduate students to be enrolled in the graduate studies programs in the department.
5. Member of the Committee for follow up of implementation of the faculty 5-year strategic plan (2015-2020) from September 2018 to August 2019.
6. Member of the “Academic Standards and Educational Programs Committee” from November 2014 to July 2015. Participating in the process of formulating and updating the academic standards for both programs within the Faculty of Pharmacy, Cairo University.
7. Member of “The Interdisciplinary Research Committee” responsible for putting down the regulations for submitting and reviewing interdisciplinary research grants applications. Also overseeing the research projects carried out by the undergraduate students.

8. Coordinator of “The Soat Al-Mostakabel Committee” from October 2011 to September 2012. Responsible for overseeing the teaching assistants and assistant lecturer’s affairs in the faculty by serving as a communicating channel between them and the faculty administration.
9. Member of “The Experts Committee” responsible for putting down suggestions for the improvement of the laws governing the Egyptian Universities.
10. Consultant to “The Scientific Research and Technology Committee” of the student union of the Faculty of Pharmacy, Cairo University from 2011 to 2015. Supervising activities such as (Scientific trips, scientific workshops, and scientific competitions).